Advertisement
U.S. markets closed

Avalo Therapeutics, Inc. (AVTX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
4.4200+0.0100 (+0.23%)
At close: 03:59PM EST
4.6500 +0.23 (+5.20%)
After hours: 08:00PM EST
Advertisement
Show:
Annual
Subscribe to Yahoo Finance Plus Essential to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Breakdown
ttm
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,249
18,051
5,398
6,699
Cost of Revenue
2,125
3,434
1,491
300
Gross Profit
124
14,617
3,907
6,399
Operating Expense
28,672
52,057
86,041
53,693
Operating Income
-28,548
-37,440
-82,134
-47,294
Net Non Operating Interest Income Expense
-4,447
-4,170
-2,391
49
Other Income Expense
-162
-20
-20
-19,932
Pretax Income
-33,157
-41,630
-84,545
-67,177
Tax Provision
31
28
-196
-2,793
Net Income Common Stockholders
-33,188
-41,658
-84,376
-57,638
Diluted NI Available to Com Stockholders
-33,188
-41,658
-84,376
-57,638
Basic EPS
-480.00
-1.06k
-2.39k
-2.48k
Diluted EPS
-480.00
-1.06k
-2.39k
-2.48k
Basic Average Shares
85.69
39.182
35.298
1,283
Diluted Average Shares
85.69
39.182
35.298
1,283
Total Expenses
30,797
55,491
87,532
53,993
Net Income from Continuing & Discontinued Operation
-33,188
-41,658
-84,376
-63,500
Normalized Income
-33,093
-41,658
-84,349
-44,899
Interest Income
-
-
-
48.873
Interest Expense
4,447
4,170
2,391
-
Net Interest Income
-4,447
-4,170
-2,391
49
EBIT
-28,710
-37,460
-82,154
-47,294
EBITDA
-28,560
-37,294
-80,497
-45,451
Reconciled Cost of Revenue
1,975
3,306
1,382
198
Reconciled Depreciation
150
166
1,657
1,843
Net Income from Continuing Operation Net Minority Interest
-33,188
-41,658
-84,349
-64,384
Total Unusual Items Excluding Goodwill
-120
-
0
-20,341
Total Unusual Items
-120
-
0
-20,341
Normalized EBITDA
-28,440
-37,294
-80,497
-25,110
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
-25.2
0
0
-856.3561